EP0961619A4 - Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques - Google Patents

Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques

Info

Publication number
EP0961619A4
EP0961619A4 EP97944519A EP97944519A EP0961619A4 EP 0961619 A4 EP0961619 A4 EP 0961619A4 EP 97944519 A EP97944519 A EP 97944519A EP 97944519 A EP97944519 A EP 97944519A EP 0961619 A4 EP0961619 A4 EP 0961619A4
Authority
EP
European Patent Office
Prior art keywords
delivery
anticancer drugs
metastatic cells
hydrolyzable prodrugs
hydrolyzable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97944519A
Other languages
German (de)
English (en)
Other versions
EP0961619A1 (fr
Inventor
Raymond Firestone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0961619A1 publication Critical patent/EP0961619A1/fr
Publication of EP0961619A4 publication Critical patent/EP0961619A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97944519A 1996-09-27 1997-09-25 Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques Withdrawn EP0961619A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4433496P 1996-09-27 1996-09-27
US44334P 1996-09-27
PCT/US1997/017410 WO1998013059A1 (fr) 1996-09-27 1997-09-25 Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques

Publications (2)

Publication Number Publication Date
EP0961619A1 EP0961619A1 (fr) 1999-12-08
EP0961619A4 true EP0961619A4 (fr) 2001-09-26

Family

ID=21931799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97944519A Withdrawn EP0961619A4 (fr) 1996-09-27 1997-09-25 Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques

Country Status (4)

Country Link
EP (1) EP0961619A4 (fr)
AU (1) AU739028B2 (fr)
CA (1) CA2264227A1 (fr)
WO (1) WO1998013059A1 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
WO1999025729A1 (fr) * 1997-11-18 1999-05-27 Chugai Seiyaku Kabushiki Kaisha Composes possedant une activite antitumorale
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999030727A1 (fr) 1997-12-17 1999-06-24 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6835807B1 (en) 1998-05-22 2004-12-28 Daiichi Pharmaceuticals Co., Ltd. Drug complex and drug delivery system
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
JP2002530059A (ja) 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
WO2000050059A1 (fr) * 1999-02-24 2000-08-31 The Uab Research Foundation Derives de taxane pour therapie ciblee contre le cancer
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
JP2002544242A (ja) * 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物
CA2383798A1 (fr) * 1999-09-07 2001-03-15 Conjuchem Inc. Diffusion pulmonaire permettant la bioconjugaison
AU7570201A (en) * 2000-07-26 2002-02-05 Riley Patrick Anthony Phenylethylamine derivatives and their use in the treatment of melanoma
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2002042295A2 (fr) 2000-11-01 2002-05-30 Praecis Pharmaceuticals Inc. Agents therapeutiques et procede d'utilisation de ces derniers pour modules l'angiogenese
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
EP1243276A1 (fr) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Prodrogues activables à séparateurs allongés et multiples
BR0210149A (pt) * 2001-05-09 2004-06-29 Newbiotics Inc Pródrogas ativadas por deformilase de peptìdeo
YU44404A (sh) * 2001-11-23 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Postupak za identifikovanje ciljnih enzima tumora
DK2327705T3 (en) 2001-12-03 2015-08-24 Universitätsklinikum Charité Der Humboldt Universität Zu Berlin Podophyllotoxins as antiproliferative agents
US20030219402A1 (en) * 2002-02-14 2003-11-27 Rutter William J. Chimeric molecules for cleavage in a treated host
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
EP1545613B9 (fr) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Conjugues d'auristatine et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
US20050271615A1 (en) * 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
BR0315537A (pt) 2002-11-14 2005-09-27 Celmed Oncology Usa Inc Pró-drogas ativadas por peptìdeo desformilase
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
EP2390262A1 (fr) 2003-05-16 2011-11-30 Intermune, Inc. Ligands de récepteur de chimiokine synthétique et leurs procédés d'utilisation
CA2536357A1 (fr) 2003-05-29 2004-12-23 The Scripps Research Institute Liberation ciblee sur des cellules exprimant la legumaine
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005082023A2 (fr) 2004-02-23 2005-09-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
UA88008C2 (en) 2004-04-09 2009-09-10 Чугей Сейяку Кабусики Кайся Water-soluble prodrugs
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2007008603A1 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CA2692417C (fr) 2007-07-03 2017-03-21 Children's Hospital & Research Center At Oakland Derives d'acide polysialique, procedes de production, et utilisations pour ameliorer la production et le ciblage d'antigenes de cancers
MY157165A (en) 2008-04-30 2016-05-13 Immunogen Inc Cross-linkers and their uses
CA2724550C (fr) 2008-05-22 2017-01-03 Kereos, Inc. Combinaison therapeutique anticancereuse
EP2310507A4 (fr) 2008-07-08 2013-03-20 David Gladstone Inst Procédés et compositions de modulation de l'angiogenèse
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
CN102504013B (zh) * 2011-09-28 2014-03-26 李雁 一种靶向抗癌转移化学药物padm及制备方法和用途
WO2013063702A1 (fr) 2011-11-04 2013-05-10 Zymeworks Inc. Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc
EP2804873A4 (fr) * 2012-01-18 2015-12-23 Raymond A Firestone Compositions et méthodes utilisables en vue du traitement de cancers et de maladies et affections associées à l'inflammation
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
US9470693B2 (en) 2012-05-18 2016-10-18 University Of North Dakota Method for quantifying proteins and isoforms thereof
WO2013177481A1 (fr) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazépines et leurs conjugués
EP3539563A1 (fr) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Anticorps spécifique pour cd22 et ses procédés d'utilisation
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
BR112015008173A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolobenzodiazepina-anticorpo anti-psma
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
SI2839860T1 (sl) 2012-10-12 2019-07-31 MedImmune Limited, Pirolobenzodiazepini in njihovi konjugati
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
EP2912177A1 (fr) 2012-10-23 2015-09-02 Cornell University Traitement du cancer du sein métastatique
KR20150083121A (ko) 2012-11-12 2015-07-16 레드우드 바이오사이언스 인코포레이티드 화합물, 및 컨쥬게이트의 제조방법
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EP2935268B2 (fr) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazépines et conjugués associés
ES2868247T3 (es) 2013-02-15 2021-10-21 Univ California Receptor de antígeno quimérico y métodos de uso del mismo
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
WO2015038426A1 (fr) * 2013-09-13 2015-03-19 Asana Biosciences, Llc Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépines
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
WO2015081282A1 (fr) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
CN106458910B (zh) 2014-02-19 2020-11-06 亚倍生技制药公司 线粒体醛脱氢酶2(aldh2)结合多环酰胺和其用于治疗癌症的用途
EP3125943A4 (fr) 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Lieurs à base de phosphates pour introduction intracellulaire de conjugués médicamenteux
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
WO2017083637A1 (fr) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Oligophosphotriesters riches en guanidinium à pénétration cellulaire pour l'administration de médicament et de sonde
EP3377523A4 (fr) 2015-11-19 2019-06-19 The Regents of The University of California Récepteurs de cellules immunitaires répressibles sous conditions et leurs procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
EP3407916B1 (fr) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Lieurs de phosphonate et leur utilisation pour faciliter la rétention cellulaire de composés
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3231421A1 (fr) 2016-04-11 2017-10-18 Greenaltech, S.L. Utilisations d'un caroténoïde dans le traitement ou la prévention d'états induits par le stress
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP4019007A1 (fr) 2016-06-01 2022-06-29 Servier IP UK Limited Formulations d'oxyde de polyalkylène-asparaginase et leurs procédés de fabrication et d'utilisation
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3388082A1 (fr) 2017-04-13 2018-10-17 Galera Labs, LLC Poly-immunothérapie anticancéreuse avec un complexe de cycle pentaaza macrocyclique
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
CN110536703A (zh) 2017-04-20 2019-12-03 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
CN111065638B (zh) 2017-08-18 2021-04-09 麦迪穆有限责任公司 吡咯并苯并二氮杂䓬缀合物
EP3505188A1 (fr) 2017-12-29 2019-07-03 Invivogen Conjugués de dinucléotide pro-cycliques pour l'induction de la cytokine
WO2019152661A1 (fr) 2018-01-31 2019-08-08 Galera Labs, Llc Polythérapie anticancéreuse au moyen d'un complexe de type cycle macrocyclique pentaaza et d'un agent anticancéreux à base de platine
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019200181A1 (fr) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Procédés et compositions pour microparticules à libération prolongée pour l'administration de médicament oculaire
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108383757A (zh) * 2018-04-12 2018-08-10 江苏金斯瑞生物科技有限公司 一种Nε-叔丁氧羰基-Nα-芴甲氧羰基-Nε-甲基-赖氨酸的制备方法
EP3823674A4 (fr) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. Conjugués pour administrer un agent anticancéreux à des cellules nerveuses, méthodes d'utilisation et leurs procédés de fabrication
WO2020206033A1 (fr) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Anticorps multi-spécifiques d'un antigène associé à un cancer et d'une pompe d'efflux, ainsi que compositions, réactifs, kits et méthodes associés à ceux-ci
WO2020216947A1 (fr) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Conjugués anticorps-médicaments d'amatoxine et leurs utilisations
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN115023443A (zh) 2020-01-29 2022-09-06 肯乔克蒂生物技术股份有限公司 抗mdr1抗体及其用途
CN116323662A (zh) 2020-06-04 2023-06-23 肯乔克蒂生物技术股份有限公司 抗abcg2抗体及其用途
CA3182969A1 (fr) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anticorps multi-specifiques d'un antigene associe a un cancer-pompe a efflux, ainsi que compositions, reactifs, kits et methodes associes a ceux-ci
WO2022043256A1 (fr) 2020-08-23 2022-03-03 Cobiores Nv Combinaisons synergiques de médicaments anticancéreux liés à une fraction tétrapeptidique et d'agents immunothérapeutiques
AU2021338286A1 (en) 2020-09-02 2023-03-23 Kenjockety Biotechnology, Inc. Anti-ABCC1 antibodies and uses thereof
WO2022103603A1 (fr) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anticorps anti-mrp4 (codés par le gène abcc4) et leurs utilisations
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique
WO2023114658A1 (fr) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anticorps anti-abcb1
WO2023159220A1 (fr) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anticorps anti-cd47
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019705A1 (fr) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Sequences de liaison peptidiques ramifiees

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019705A1 (fr) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Sequences de liaison peptidiques ramifiees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUBOWCHIK, GENE M. ET AL: "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin", BIOORG. MED. CHEM. LETT. (1998), 8(23), 3341-3346, XP002172918 *
DUBOWCHIK, GENE M. ET AL: "Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (taxol), mitomycin C and doxorubicin", BIOORG. MED. CHEM. LETT. (1998), 8(23), 3347-3352, XP002172917 *
DUBOWCHIK, GENE M. ET AL: "Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles", TETRAHEDRON LETT. (1997), 38(30), 5257-5260, July 1997 (1997-07-01), XP002172916 *
See also references of WO9813059A1 *

Also Published As

Publication number Publication date
WO1998013059A1 (fr) 1998-04-02
EP0961619A1 (fr) 1999-12-08
AU4599597A (en) 1998-04-17
AU739028B2 (en) 2001-10-04
CA2264227A1 (fr) 1998-04-02

Similar Documents

Publication Publication Date Title
EP0961619A4 (fr) Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques
EP1416920A4 (fr) Systeme multiplexe de liberation de medicaments approprie a l'administration par voie orale
AU8399298A (en) Process for preparing fast dispersing solid oral dosage form
PL339864A1 (en) Preparation containing 2-methylthiene benzodiazepin
AU4400797A (en) Colon selective drug delivery composition
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
AU9223098A (en) Dosage form comprising means for changing drug delivery shape
EP0965597A4 (fr) Medicaments diriges vers la membrane cellulaire
AU1694400A (en) Transdermal delivery system containing buprenorphine
FR2751645B1 (fr) Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
EP1004296A4 (fr) Poudre contenant un medicament liposoluble
EP0821963A4 (fr) Substance anticancereuse inhibant le processus metastatique cancereux
HU9603206D0 (en) Transdermal delivery of anti-epileptic drugs
GB9601186D0 (en) Administration of Drugs
PL337722A1 (en) Novel combination antiasthmatic drugs
AU6027899A (en) Local delivery of medications to the heart
IL133085A0 (en) Ganglioside gm3 induced apoptosis of neural cells
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
GB9930499D0 (en) Delivery of substances to cells
AU6878198A (en) Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
IL121349A0 (en) Delivery of substances to injured site of the central nervous system
GB9605726D0 (en) Delivery of drugs etc
AU2002300727A1 (en) Ganglioside GM3 Induced Apoptosis of Neural Cells
GB9705835D0 (en) Delivery of drugs etc
HU9602904D0 (en) Pharmaceutical compositions containing taxanes of anti-cancer activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010813

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040906